http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1289495-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9433d383d1922b3df0ca6c182c7d3925
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-04
filingDate 2001-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b2fb4b73c2c1ac23e6a7996ceb1feab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ce0f96944ff7eb3c99ecb04ed1e2f43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f91928b09158348842c8aed0df9540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b39b206e969bfaf1dbf34a7d40f8390e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470b45db57b145e8f93863e15863f913
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f4844a8b905a3518bc4702577194328
publicationDate 2003-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1289495-A1
titleOfInvention Process for the preparation of a sterile ointment containing acyclovir
abstract The invention refers to a process for the preparation of a sterile ointment, especially an eye ointment, containing acyclovir or a pharmaceutically suitable acid addition salt thereof as the active ingredient by homogenizing micronized acyclovir or a pharmaceutically acceptable acid addition salt thereof and the sterile carriers of the ointment in an aseptic way, then filling the homogenous ointment into sterile containers and sealing the containers. According to the process of the invention, 1 part by mass of acyclovir or a pharmaceutically suitable acid addition salt thereof consisting of particles that are lower in size than 60 mu m, preferably 20 mu m, are admixed to 1-30 parts by mass of vaseline and/or liquid paraffin and/or a mixture of solid and liquid paraffin, the mixture is hermetically sealed and kept at 120-150 DEG C for 0.3-5 hours, and the sterile mixture obtained is homogenized with a further sterile portion of the carriers in an aseptic way in a manner knows <i>per se.</i>
priorityDate 2000-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10953859
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226490652
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398513
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID185639
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394130
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226490651
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394131
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID79075
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395421
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93066
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2682
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409824
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135761770
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226404050
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396472
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10206907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID103023
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406514
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128610196
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226404049
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394458
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6054
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6455927
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226512630
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395574
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24699

Total number of triples: 58.